SIRPa is the ligand of CD47, a molecule upregulated on many hematological and solid tumors. CD47 delivers a "do not eat" signal that su ppresses macrophage phagocytosis, allowing cancer cells, including cancer stem cells, to escape immune-mediated destruction.
"Targeting the CD47/SIRPa pathway can eliminate bot h bulk cancer cells and cancer stem cells, and engages both the innate and the adaptive arms of the immune system," commented SCT's Chief Scientific Officer, Dr.
"The CD47/SIRPa axis is one of the most promising a nd compelling next-generation immunotherapy targets in the fight against cancer," remarked SCT's Chief Executive Officer, Dr.
The execution of the definitive license agreement is subject to final due-diligence and certain conditions being met by SCT over the next nine months. The license agreement will contain customary terms and provisions for assets at this stage of development, including an initial license consideration, milestone payments, royalties on sales and sublicensing terms.
SCT Annual and Special Meeting
The company's Annual and Special Meeting of shareholders will be held today at
Most Popular Stories
- Bipartisan Budget Deal Gets Key Support in House
- Bitcoin Clones Lurch Onto Financial Scene
- Clinton to Keynote Annual Simmons Leadership Conference
- Scotch Whisky Sales Raise Distillers' Spirits
- Holiday Shopping Off to a Slow Start This Season
- Budget Deal Will Cut 220,000 Californians Out of Jobless Benefits
- Fake Deaf Interpreter Was Hallucinating, Has Schizophrenia
- Tea Party Glum in Face of Bipartisan Budget Deal
- Health Coverage Disparities Emerge Among States
- Futures Fall, Holiday Spending and Unemployment Up